News
Drug can address unmet need in cHL, doc says
COPENHAGEN—The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have...
News
ESA benefits lower-risk MDS patients
COPENHAGEN—The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic...
News
Immunotherapy ‘outcompetes’ chemo in rel/ref B-ALL
COPENHAGEN—Interim results from the phase 3 TOWER trial suggest blinatumomab can prolong overall survival (OS) when compared to standard care in...
News
A new standard of care for relapsed/refractory MM?
COPENHAGEN—The combination of daratumumab, lenalidomide, and dexamethasone (DRd) could become a new standard of care for patients with relapsed or...
News
Combo can produce durable remissions in PTCL
Photo by Larry Young SAN FRANCISCO—A combination treatment regimen can produce durable remissions in patients newly diagnosed with peripheral T-...
News
Chemo regimen can be ‘highly effective’ against ENKTL
Photo by Larry Young SAN FRANCISCO—A 3-agent chemotherapy regimen can be “highly effective” in patients with extranodal natural killer/T-cell...
News
Dual inhibitor could treat ATLL
Photo by Larry Young SAN FRANCISCO—Preclinical research suggests a compound that inhibits both EZH1 and EZH2 could be effective against adult T-...
News
Immunotherapy proves active against MF, SS
Photo by Larry Young SAN FRANCISCO—The PD-1-blocking antibody pembrolizumab can produce “significant objective clinical responses” in patients...
News
Mutations may impact response to HDACis in PTCL-NOS
Photo by Larry Young SAN FRANCISCO—Preclinical research has revealed mutations that may affect the performance of histone deacetylase inhibitors...
News
Lenalidomide shows promise for treating ATLL
Photo by Larry Young SAN FRANCISCO—Results of a phase 2 trial suggest lenalidomide may be a treatment option for patients with relapsed adult T-...
News
Study suggests chidamide could treat rel/ref CTCL too
Photo by Larry Young SAN FRANCISCO—The oral histone deacetylase inhibitor chidamide can elicit responses in patients with relapsed or refractory...
News
A new standard of care for rel/ref MM?
Photo courtesy of ASH ORLANDO, FL—Adding the oral proteasome inhibitor ixazomib to treatment with lenalidomide and dexamethasone can prolong...
News
High-risk B-ALL subgroup has ‘outstanding outcomes’
Photo courtesy of ASH ORLANDO, FL—A subgroup of young patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL) can have “outstanding...
News
BM fibrosis grade may impact OS in PMF
ORLANDO, FL—Having a higher grade of bone marrow (BM) fibrosis may confer inferior overall survival (OS) in patients with primary myelofibrosis (...
News
EZH2 inhibitor can produce durable responses
ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with...